Fierce Biotech February 6, 2025
Gabrielle Masson, Darren Incorvaia

We hoped industry layoffs would relent in 2024. That’s not what happened.

Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data.

So, here we are, launching our fourth edition of Fierce Biotech’s layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team and let us know.

February—2 companies

Feb. 4 – Turnstone Biologics: The San Diego is seeking out “strategic alternatives” for its business and as it cuts work on a key pipeline program, it’s also wielding the ax on its staffers. By exactly how much, the biotech is not sharing, saying simply that it is “reducing its...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Stakeholder Management and Interoperability of Biosimilars
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
Pharma Pulse 2/21/25: RWE in Medical Research and Drug Development, Inhaled Antibody Therapy for RSV & more
FDA approves first rapid-acting insulin biosimilar for diabetes

Share This Article